Active Filter(s):
Details:
The net proceeds will be used to fund the clinical trial for WCK 5222, a combination of cefepime and the novel β-lactam enhancer (BLE) zidebactam, currently being studied in a global Phase 3 trial in complicated urinary tract infection.
Lead Product(s): Cefepime,Zidebactam
Therapeutic Area: Infections and Infectious Diseases Product Name: WCK 5222
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: ICICI Prudential
Deal Size: $57.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 28, 2024